Subscribe
27 January 2015Americas

Generics urge US Supreme Court to implement Copaxone ruling

Generic drug makers Sandoz, Mylan and Natco have asked the US Supreme Court to immediately put into effect its ruling on the validity of a patent covering Teva’s multi-billion dollar multiple sclerosis drug Copaxone.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Generics petition Supreme Court to save PTAB patent trials
7 January 2021   Generic drug makers are trying to persuade the US Supreme Court to retain an administrative process for challenging patents, in the latest bid to discredit the controversial decision handed down in Arthrex v Smith & Nephew.


Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024

Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024
Americas
Earthquake Chevron: A massive shock to the system?
2 July 2024
Americas
Amarin wins appeal to advance ‘skinny label’ suit over Hikma generic
27 June 2024
Biotechnology
Guardant Health files suit against Tempus AI
13 June 2024
Big Pharma
Roche fires lawsuit at Sinocare unit over blood glucose test strip patents
6 June 2024

More on this story

Americas
Generics petition Supreme Court to save PTAB patent trials
7 January 2021   Generic drug makers are trying to persuade the US Supreme Court to retain an administrative process for challenging patents, in the latest bid to discredit the controversial decision handed down in Arthrex v Smith & Nephew.

More on this story

Americas
Generics petition Supreme Court to save PTAB patent trials
7 January 2021   Generic drug makers are trying to persuade the US Supreme Court to retain an administrative process for challenging patents, in the latest bid to discredit the controversial decision handed down in Arthrex v Smith & Nephew.

More features

Chinese biotech takes out US rival’s nucleic acid patent at PTAB
Lewis Roca promotes tech expert to managing partner
Panitch Schwarze brings in molecular biologist
US targets ‘product hopping’ with biologic litigation curbs
UPC confirms validity of Edwards Lifesciences heart valve tech patent
ITC concludes row over biotech lab equipment between US and German rivals
UKIPO launches ‘revolutionary’ patent filing and AI tool
USPTO clarifies AI's role in patent eligibility